Advanced search
Publication Cover
OncoImmunology Volume 9, 2020 - Issue 1
Submit an article Journal homepage
1,139
Views
12
CrossRef citations to date
0
Altmetric
Brief Report

Increased occurrence of status epilepticus in patients with brain metastases and checkpoint inhibition

Hans Urbana Dr. Senckenberg Institute of Neurooncology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany;b University Cancer Center Frankfurt (UCT), University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany;c German Cancer Consortium (DKTK), Partner Site Frankfurt/Mainz, Frankfurt am Main, GermanyCorrespondence[email protected]
View further author information
,
Laurent M. Willemsd Epilepsy Center Frankfurt Rhine-Main and Department of Neurology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany;e Center for Personalized Translational Epilepsy Research (Cepter), University Hospital Frankfurt, Goethe University, Frankfurt am Main, GermanyORCID Iconhttps://orcid.org/0000-0001-8226-1674View further author information
ORCID Icon,
Michael W. Ronellenfitscha Dr. Senckenberg Institute of Neurooncology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany;b University Cancer Center Frankfurt (UCT), University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany;c German Cancer Consortium (DKTK), Partner Site Frankfurt/Mainz, Frankfurt am Main, Germany;e Center for Personalized Translational Epilepsy Research (Cepter), University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany;f Frankfurt Cancer Institute (FCI), University Hospital Frankfurt, Goethe University, Frankfurt am Main, GermanyView further author information
,
Felix Rosenowd Epilepsy Center Frankfurt Rhine-Main and Department of Neurology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany;e Center for Personalized Translational Epilepsy Research (Cepter), University Hospital Frankfurt, Goethe University, Frankfurt am Main, GermanyView further author information
,
Joachim P. Steinbacha Dr. Senckenberg Institute of Neurooncology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany;b University Cancer Center Frankfurt (UCT), University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany;c German Cancer Consortium (DKTK), Partner Site Frankfurt/Mainz, Frankfurt am Main, Germany;f Frankfurt Cancer Institute (FCI), University Hospital Frankfurt, Goethe University, Frankfurt am Main, GermanyORCID Iconhttps://orcid.org/0000-0002-4695-2483View further author information
ORCID Icon &
Adam Strzelczykd Epilepsy Center Frankfurt Rhine-Main and Department of Neurology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany;e Center for Personalized Translational Epilepsy Research (Cepter), University Hospital Frankfurt, Goethe University, Frankfurt am Main, GermanyORCID Iconhttps://orcid.org/0000-0001-6288-9915View further author information
ORCID Icon
Article: 1851517 | Received 23 Jul 2020, Accepted 11 Nov 2020, Published online: 29 Nov 2020

References

  • Arik Y, Leijten FS, Seute T, Robe PA, Snijders TJ. Prognosis and therapy of tumor-related versus non-tumor-related status epilepticus: a systematic review and meta-analysis. BMC Neurol. 2014;14:152. doi:10.1186/1471-2377-14-152.
  • Betjemann JP, Lowenstein DH. Status epilepticus in adults. Lancet Neurol. 2015;14:615–6. doi:10.1016/S1474-4422(15)00042-3.
  • Rossetti AO, Hurwitz S, Logroscino G, Bromfield EB. Prognosis of status epilepticus: role of aetiology, age, and consciousness impairment at presentation. J Neurol Neurosurg Psychiatry. 2006;77:611–615. doi:10.1136/jnnp.2005.080887.
  • Hoos A. Development of immuno-oncology drugs – from CTLA4 to PD1 to the next generations. Nat Rev Drug Discov. 2016;15:235–247. doi:10.1038/nrd.2015.35.
  • Dalakas MC. Neurological complications of immune checkpoint inhibitors: what happens when you ‘take the brakes off’ the immune system. Ther Adv Neurol Disord. 2018;11:1756286418799864. doi:10.1177/1756286418799864.
  • Wick W, Hertenstein A, Platten M. Neurological sequelae of cancer immunotherapies and targeted therapies. Lancet Oncol. 2016;17:e529–e541. doi:10.1016/S1470-2045(16)30571-X.
  • Vezzani A, Dingledine R, Rossetti AO. Immunity and inflammation in status epilepticus and its sequelae: possibilities for therapeutic application. Expert Rev Neurother. 2015;15:1081–1092. doi:10.1586/14737175.2015.1079130.
  • Berghoff AS, Preusser M. The inflammatory microenvironment in brain metastases: potential treatment target? Chin Clin Oncol. 2015;4:21.
  • Kortland LM, Alfter A, Bahr O, Carl B, Dodel R, Freiman TM, Hubert K, Jahnke K, Knake S, von Podewils F, et al. Costs and cost-driving factors for acute treatment of adults with status epilepticus: a multicenter cohort study from Germany. Epilepsia. 2016;57:2056–2066. doi:10.1111/epi.13584.
  • Trinka E, Cock H, Hesdorffer D, Rossetti AO, Scheffer IE, Shinnar S, Shorvon S, Lowenstein DH. A definition and classification of status epilepticus – report of the ILAE task force on classification of status epilepticus. Epilepsia. 2015;56:1515–1523. doi:10.1111/epi.13121.
  • Tran TT, Mahajan A, Chiang VL, Goldberg SB, Nguyen DX, Jilaveanu LB, Kluger HM. Perilesional edema in brain metastases: potential causes and implications for treatment with immune therapy. J Immunother Cancer. 2019;7:200. doi:10.1186/s40425-019-0684-z
  • Schneider S, Potthast S, Komminoth P, Schwegler G, Bohm SPD-1. Checkpoint inhibitor associated autoimmune encephalitis. Case Rep Oncol. 2017;10:473–478. doi:10.1159/000477162.
  • Lyons S, Joyce R, Moynagh P, O’Donnell L, Blazkova S, Counihan TJ. Autoimmune encephalitis associated with Ma2 antibodies and immune checkpoint inhibitor therapy. Pract Neurol. 2020;20:256–259. doi:10.1136/practneurol-2019-002464.
  • Alvarez V, Januel JM, Burnand B, Rossetti AO. Role of comorbidities in outcome prediction after status epilepticus. Epilepsia. 2012;53:e89–92. doi:10.1111/j.1528-1167.2012.03451.x.
  • Sutter R, Semmlack S, Kaplan PW, Opic P, Marsch S, Ruegg S. Prolonged status epilepticus: early recognition and prediction of full recovery in a 12-year cohort. Epilepsia. 2019;60:42–52. doi:10.1111/epi.14603.
  • Kellinghaus C, Rossetti AO, Trinka E, Lang N, May TW, Unterberger I, Rüegg S, Sutter R, Strzelczyk A, Tilz C, et al. Factors predicting cessation of status epilepticus in clinical practice: data from a prospective observational registry (SENSE). Ann Neurol. 2019;85:421–432. doi: 10.1002/ana.25416.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.